Raltegravir alleviates endoplasmic reticulum (ER) stress and thereby suppresses HIV protease inhibitor-induced inflammation (8), while simultaneously inhibiting the nucleotide-binding oligomerization domain-like receptor 3 (NLRP3) inflammasome and thus preventing lung fibrosis (9). This evidence concerns the gene NLRP3 and pulmonary fibrosis.